Talphera

TLPHPhase 3

San Mateo, United StatesFounded 2011talphera.com

Talphera, formerly known as AcelRx Pharmaceuticals, has pivoted from acute pain management to a broader mission of developing products for medically supervised settings following the divestment of its acute pain product in 2023. The company's strategy centers on nafamostat, a serine protease inhibitor with anticoagulant, anti-inflammatory, and antiviral properties, creating a 'pipeline-in-a-product.' With Niyad granted FDA Breakthrough Device designation and top-line data expected by the end of 2025, Talphera is positioned to address a significant unmet need in renal care while exploring additional applications for its core asset.

Market Cap

$4.7B

Founded

2011

Focus

Drug DeliverySmall Molecules

TLPH · Stock Price

USD 100.80+9.80 (+10.77%)

Historical price data

AI Company Overview

Technology Platform

Development of a 'pipeline-in-a-product' based on nafamostat mesylate, a broad-spectrum serine protease inhibitor with an ultrashort 8-minute half-life, exploiting its anticoagulant, anti-inflammatory, and antiviral properties for multiple applications in medically supervised settings.

Pipeline Snapshot

17 drugs in pipeline, 7 in Phase 3

Drug	Indication	Stage
Sufentanil NanoTab PCA System/15 mcg + morphine IV PCA	Post-Operative Pain	Phase 3
sufentanil sublingual tablet 30 mcg	Acute Moderate-to-severe Pain	Phase 3
Sufentanil Tablet 30 mcg + Placebo Tablet	Post-Operative Pain	Phase 3
Sufentanil NanoTab PCA System/15 mcg + Placebo Sufentanil NanoTab PCA System	Post-Operative Pain	Phase 3
sufentanil sublingual 30 mcg tablet	Moderate-to-severe Acute Pain	Phase 3

Opportunities

The primary opportunity is establishing Niyad as the first FDA-approved regional anticoagulant for RRT, capturing a significant share of the underserved patient population unable to use heparin.

Success with nafamostat could unlock a 'pipeline-in-a-product' with multiple high-value indications in critical care and inflammatory diseases through LTX-608.

Risk Factors

Key risks include clinical trial failure of the lead Niyad program, insufficient funding to reach commercialization, regulatory hurdles in obtaining PMA/NDA approvals, and challenges in commercializing hospital-based products without a strong partner.

Competitive Landscape

Niyad competes against off-label use of citrate and direct thrombin inhibitors in RRT, and against the entrenched standard, heparin. Its differentiation is its regional activity, short half-life, and pursuit of FDA approval. LTX-608 would face competition from numerous approved therapies across its target inflammatory and viral indications.